Reduction of Depression in Diabetes: A New Pleiotropic Action of Metformin?

Stella Papachristou · Nikolaos Papanas

ABSTRACT

Metformin remains the cornerstone of management for type 2 diabetes mellitus (T2DM). It is also known that it has beneficial pleiotropic actions. In addition, there is emerging evidence that this agent may prove beneficial in ameliorating depression in T2DM. The underlying mechanisms of this new action remain elusive, but experimental studies point to improved synaptic function and increased serotonin activity, along with the known inflammatory and antioxidant properties of metformin. Obviously, we need to further explore the potential utility of such antidepressant effects among T2DM subjects in everyday reality.

Keywords: Antidiabetic treatment; Depression; Metformin; Pleiotropic; Type 2 diabetes

DIGITAL FEATURES

To view any digital features for this article, go to https://doi.org/10.6084/m9.figshare.14113622.
bipolar disorder or major depression with psychotic features; overweight or obesity; weight gain of >10%. These were randomised to add-on metformin, switch of antipsychotic agents or continuation of baseline antipsychotic therapy [9]. Subjects receiving metformin exhibited a significant improvement in the social life subscale [9]. Predictably, this agent also exerted beneficial actions in BMI, prevention of weight increase and fasting glucose [9].

The mechanisms underlying such favourable effects are still unclear. Some relevant evidence comes from experimental studies (Table 1). In male mice, metformin has been shown to ameliorate depression via enhancing the expression of brain-derived neurotrophic factor (BDNF) by activating 5’ adenosine monophosphate-activated protein kinase (AMPK)/AMP response element-binding protein (CREB)-mediated histone acetylation when combined with fluoxetine [10]. Ribonucleic acid (RNA) sequencing and Golgi-staining revealed that metformin prevented impaired synaptic functions in the hippocampal circuit [10]. Again in the diabetic depressed rat model, metformin monotherapy or metformin plus ascorbic acid exerted an antidepressant effect, as evidenced by the reduction in immobility time in forced swim test (FST) [11]. The antidepressant effect of metformin could be attributed to the elevation of serotonin and norepinephrine in the brain [11]. In addition, its antidepressant effect appeared to be caused by the reduction of plasma corticosterone levels and adrenocorticotropic hormone (ACTH) secretion via the AMPK/liver X receptor α/pro-opiomelanocortin pathway [11]. Metformin has also been shown to act against methamphetamine-induced behavioural changes in rats with experimental diabetes [12]. This protective effect was associated with improved neurotransmission [11, 12]. Further postulated mechanisms include the anti-inflammatory and antioxidant properties of metformin [12].

Finally, peripheral insulin resistance has been associated with anxiogenic-like responses [13]. The latter are associated with increased branched-chain amino acid plasma levels, which in turn reduce tryptophan availability in serotonin receptors [13, 14]. In this context, it is of immense interest that hippocampal serotonin re-uptake was reduced among metformin-treated insulin-resistant mice [14]. These findings pave the way for the consideration of metformin plus serotonin re-uptake inhibitors for the treatment of depression, but it is far too early to draw safe conclusions in humans.

In conclusion, there is accumulating data that the new pleiotropic effect of metformin may be an anti-psychotic, mainly anti-depressive action in the setting of diabetes. The underlying mechanisms of this new postulated action remain elusive, but experimental evidence points to improved synaptic function and increased serotonin activity along with the known anti-inflammatory and antioxidant properties of metformin [10–12]. It is still unclear whether this is of real relevance to humans. However, metformin has already been identified as one of the agents associated with

Table 1 Main mechanisms of action of metformin on mood, according to experimental studies

1. Ameliorate depression via enhancing the expression of BDNF by activating AMPK/AMP response element binding protein (CREB)-mediated histone acetylation [10]
2. Antidepressant effect by elevation of serotonin and norepinephrine in the brain [11]
3. Antidepressant effect due to reduction of plasma corticosterone levels and ACTH secretion via the AMPK/liver X receptor α/pro-opiomelanocortin pathway [11]
4. Protection against methamphetamine-induced behavioural changes through improved neurotransmission as well as through anti-inflammatory and anti-oxidative actions [11, 12]
5. Increase of branched chain amino acid levels in plasma to reduce tryptophan availability in serotonin receptors, which in turn reduce hippocampal serotonin re-uptake [13, 14]
reduced psychiatric hospitalisation and self-harm in subjects with serious mental illness [15]. Accordingly, we are eagerly anticipating what the future has in store for metformin in ameliorating depression among subjects with impaired glucose metabolism.

ACKNOWLEDGEMENTS

**Funding.** No funding or sponsorship was received for this study or publication of this article.

**Authorship.** All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

**Disclosures.** Nikolaos Papanas has been an advisory board member of Astra-Zeneca, Boehringer Ingelheim, MSD, Novo Nordisk, Pfizer, Takeda and TrigoCare International; has participated in sponsored studies by Astra-Zeneca, Eli-Lilly, GSK, MSD, Novo Nordisk, Novartis and Sanofi-Aventis; has received honoraria as a speaker for Astra-Zeneca, Boehringer Ingelheim, Eli-Lilly, Elpen, MSD, Mylan, Novo Nordisk, Pfizer, Sanofi-Aventis and Vianex; and attended conferences sponsored by TrigoCare International, Eli-Lilly, Galenica, Novo Nordisk, Pfizer and Sanofi-Aventis. Stella Papachristou has nothing to disclose.

**Compliance with Ethics Guidelines.** This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

**Data Availability.** Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

**Open Access.** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Buse JB, Wexler DJ, Tsapas A, et al. Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2019;2020(43):487–93.

2. Papanas N, Maltezos E, Mikhailidis D. Metformin: diamonds are forever. Expert Opin Pharmacother. 2009;10:2395–7.

3. Papanas N, Maltezos E. Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering? Curr Pharm Des. 2009;15:3179–92.

4. Papanas N, Maltezos E, Mikhailidis DP. Metformin and cancer: licence to heal? Expert Opin Invest Drugs. 2010;19:913–7.

5. Penlioglou T, Papachristou S, Papanas N. COVID-19 and diabetes mellitus: may old anti-diabetic agents become the new philosopher’s stone? Diabetes Ther. 2020;11:1–3.

6. AlHussain F, AlRuthia Y, Al-Mandeel H, et al. Metformin improves the depression symptoms of women with polycystic ovary syndrome in a lifestyle modification program. Patient Prefer Adherence. 2020;14:737–46.

7. Chen F, Wie G, Wang Y, et al. Risk factors for depression in elderly diabetic patients and the effect of metformin on the condition. BMC Public Health. 2019;19:1063.
8. Guo M, Mi J, Jiang QM, et al. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin Exp Pharmacol Physiol. 2014;41:650–6.

9. Correll CU, Sikich L, Reeves G, et al. Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. World Psychiatry. 2020;19:69–80.

10. Fang W, Zhang J, Hong L, et al. Metformin ameliorates stress-induced depression-like behaviors via enhancing the expression of BDNF by activating AMPK/CREB-mediated histone acetylation. J Affect Disord. 2020;260:302–13.

11. Shivavedi N, Kumar M, Tej GNVC, Nayak PK. Metformin and ascorbic acid combination therapy ameliorates type 2 diabetes mellitus and comorbid depression in rats. Brain Res. 2017;1674:1–9.

12. Keshavarzi S, Kermanshahi S, Karami L, Motaghinejad M, Motevalian M, Sadr S. Protective role of metformin against methamphetamine induced anxiety, depression, cognition impairment and neurodegeneration in rat: the role of CREB/BDNF and Akt/GSK3 signaling pathways. Neurotoxicology. 2019;72:74–84.

13. Soliman E, Essmat N, Mahmoud MF, Mahmoud AA. Impact of some oral hypoglycemic agents on type 2 diabetes-associated depression and reserpine-induced depression in rats: the role of brain oxidative stress and inflammation. Naunyn-Schmiedeberg’s Arch Pharmacol. 2020;393:1391–404.

14. Zemdegs J, Martin H, Pintana H, et al. Metformin promotes anxiolytic and antidepressant-like responses in insulin-resistant mice by decreasing circulating branched-chain amino acids. J Neurosci. 2019;39:5935–48.

15. Hayes JF, Lundin A, Wicks S, et al. Association of hydroxymethyl glutaryl coenzyme a reductase inhibitors, L-type calcium channel antagonists, and biguanides with rates of psychiatric hospitalization and self-harm in individuals with serious mental illness. JAMA Psychiatry. 2019;76:382–90.